15 September 2021
Apollon Formularies Plc
Substantially Increases Production Capacity in
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a
• The purchase of a new state of the art distiller, increases production significantly by more than 50 fold when compared to our current level of maximum output
• The production facility expansion will lead to the generation of additional revenue for the Company through opportunities such as tolling processes and white labelling
• Installation of a specialist sonicator which allows for the production of nano-particle medicines as well as water-oil emulsions
• The acquisition of an industrial freeze drier, allowing Apollon more flexibility to store freeze dried biomass for use on demand as well as pharmaceutical applications
• Opens the path to further revenue generation opportunities to the wider domestic market before expansion to export markets in Q1 of 2022
Stephen Barnhill Jnr, COO of Apollon Jamaica, commented: "We are delighted to have expanded our state-of-the-art production facility in Negril. Our new extraction facility significantly increases our production capabilities whilst also deepening our future product offering and improving product storage. Upgrading our facility means that we have more than enough production capability to operationally support Apollon's activities as we continue our strategy to expand our local and, eventually, global footprint.
Additionally, the expansion provides the opportunity to not only generate additional revenue for the Company, through tolling agreements with local cultivators and white labelling arrangements, but also means we are able to manufacture our high-grade oils for our medical facilities and dispensaries attached to these facilities. Our team in
As a key part of the facility expansion, the Company has purchased a new imported distiller from the US which will significantly increase Apollon's high-quality cannabis oil production capability to over 50 times our current production level.
To expand its product offering, Apollon has also invested in a specialist sonicator. This technology gives the Company the ability to create any type of water-oil emulsion, including nano-emulsions, for Apollon's medicinal product line. To the Company's knowledge, Apollon's sonicator is the first of its kind being used in medical cannabis industry in
Apollon has also purchased a freeze drier which will support the Company's increased production capability by enabling the storage of fresh cannabis flowers and this will increase additional extraction capacity by double the current rate from this source.
Fundamental to Apollon's production facility expansion is the generation of additional revenue for the Company through opportunities such as tolling processes and white labelling. The Company is actively engaging with cultivators and other cannabis companies in
The expansion also supports Apollon as it continues to build its local footprint in
For additional information, please visit www.apollon.org.uk or contact:
Tel: +44 207 907 9314
Stene Jacobs email@example.com
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller firstname.lastname@example.org
Blytheweigh (Financial PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe email@example.com
Megan Ray firstname.lastname@example.org
About Apollon and Apollon Jamaica
Apollon Formularies plc is an international medical cannabis company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate, perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis in order to treat various illnesses under medical supervision. Apollon and Apollon Jamaica are parties to a Commitment Agreement whereby Apollon is entitled to 95% of Apollon Jamaica's Net Profits, and per a Stock Pledge Agreement that includes Stephen D. Barnhill, M.D., Apollon is to be assigned the entire 49% equity interest of Apollon Jamaica held by Dr. Barnhill, which is the maximum interest in a medical cannabis company allowed to be held by a non-Jamaican, upon the CLA approving the assignment.